Skip to main content
Premium Trial:

Request an Annual Quote

T2 Biosystems, Bayer Ink Hemostasis R&D Deal

NEW YORK (GenomeWeb) – T2 Biosystems announced today that it has signed a multi-year deal giving Bayer access to its T2 Magnetic Resonance (T2MR) technology platform for use in its R&D efforts in blood coagulation disorders.

Under the terms of the deal, the companies will use the technology to develop tools and evaluate assays for drug discovery and biomarker research in certain Bayer hemostasis-related programs.

Additional terms were not disclosed.

The T2MR technology uses superparamagnetic nanoparticles to measure the reaction of water molecules in the presence of magnetic fields, which is known as a T2 signal. When a binding event occurs inside a sample, the T2 signal changes, making it possible to detect the presence of an analyte.

The technology is the basis for T2's T2Candida sepsis test and its upcoming T2Bacteria bacterial sepsis assay, which is planned for a 2017 launch.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.